Fig. 7
From: VHHs as tools for therapeutic protein delivery to the central nervous system
PK/PD with anti-human TfR/BACE1 antibody. Quantification of Aβ1–40 A, B and huIgG concentrations C, D in hAPI KI mouse brains A, C and plasma B, D at day D 1, 3 and 7 after a single intravenous injection of 1A11AM-aGFP or 1A11AM-Nb188 (167 nmol/kg; low dose: 16.7 nmol/kg). Bar graphs represent mean ± SEM (n = 3–5 per group). Statistical test: two-way ANOVA with Sidak’s multiple comparisons test. A and B Significant treatment*day interaction effect for brain (***p = 0.0006), but not for plasma (ns = 0.0637). C and D. Significant treatment*day interaction effect for both brain and plasma (****p < 0.0001). E HuIgG brain over plasma ratio. Significant overall treatment effect (*p = 0.0120). Significant overall treatment effect for A, C, D, E and significant effect over time for B, C, D, E not shown